Építés alatt – nem éles oldal
Belépés
Résztvevőt keres1/2. fázis

The Safety and Efficacy of Daratumumab in Patients With Refractory Aplastic Anemia

A legfontosabb adatok

Ki végzi
Institute of Hematology & Blood Diseases Hospital, China
Hol
Kína1 helyszín, 1 országbanVálassz országot a helyszínekhez
Azonosító
Állapot
Toboroz
Fázis
1/2. fázis
Résztvevők
37 fő, tervezett
Kezdés
2025. dec. 17.
Várható befejezés
2028. dec. 31.
A vizsgálat típusa
Beavatkozással járó
A vizsgált kezelések
  • Daratumumab
A regiszteradat frissítve
2026. november 6.

Ki vehet részt

MI-összefoglaló

A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.

The trial is looking for adults with acquired aplastic anemia that did not respond to treatment or came back. Everyone gets daratumumab.

Életkor
18 years and older
Nem
All sexes
A betegség stádiuma
Primary acquired aplastic anemia, refractory (no response or relapse after treatment). Hemoglobin <90 g/L or platelet count <30×10⁹/L. ECOG performance status ≤2 (able to care for yourself). People who cannot have or do not want a stem cell transplant, with no other better treatment options.
Korábbi kezelés
Severe or transfusion-dependent non-severe disease: ATG/ALG with standard-dose cyclosporine for at least 6 months, plus a TPO receptor agonist for at least 4 months. Non-transfusion-dependent non-severe disease: standard-dose cyclosporine for at least 6 months plus a TPO receptor agonist for at least 4 months. Cannot join after prior CD38-targeted therapy, or ATG/ALG within 6 months.
Biomarker vagy leletérték
Cannot join with PNH clone ≥50%, bone marrow reticulin staining ≥ Grade 2, or MDS-type chromosome changes (except +8, 20q-, and -Y).

A részvétel fő kizáró okai

  • Inborn (congenital) bone marrow failure syndromes
  • Active infection within 2 weeks, HIV, syphilis antibody, active tuberculosis or active hepatitis B or C
  • Active bleeding, or serious heart, brain or psychiatric disease
  • B-cell or plasma-cell targeting drugs within 3 months
  • Pregnant or breastfeeding, or not willing to use highly effective contraception

A regiszter feltételei, szó szerint

Mind a 22 feltétel megnézéseKevesebb

Ki vehet részt

  • Clearly diagnosed with primary acquired aplastic anemia according to the Chinese Guidelines for the Diagnosis and Treatment of Aplastic Anemia (2022 Edition)
  • Refractory aplastic anemia meeting one of the following criteria:; 2.1 Patients previously diagnosed with severe aplastic anemia (SAA) # or transfusion-dependent non-severe aplastic anemia (TD-NSAA) \&: have received antithymocyte/antilymphocyte globulin (ATG/ALG) combined with standard-dose cyclosporine for at least 6 months, and standard-dose thrombopoietin (TPO) receptor agonist* therapy for at least 4 months, but showed no response or relapsed; 2.2 Patients previously diagnosed with non-transfusion-dependent non-severe aplastic anemia (NTD-NSAA): have received standard-dose cyclosporine for at least 6 months, and standard-dose thrombopoietin (TPO) receptor agonist* therapy for at least 4 months, but showed no response or relapsed
  • Hemoglobin <90 g/L or platelet count <30×10⁹/L
  • Not suitable for or unwilling to undergo hematopoietic stem cell transplantation; no other better treatment options available
  • Age ≥18 years, no sex limitation
  • Eastern Cooperative Oncology Group (ECOG) performance status score ≤2 (see Appendix 2)
  • Voluntarily signed the informed consent form, understands the nature, purpose, and procedures of the trial, and is willing to comply with the trial requirements

Ki nem vehet részt

  • Presence of active bacterial, viral, or fungal infection within 2 weeks prior to the first administration of the investigational drug (excluding common cold and onychomycosis), or any other severe infection. Any anti-infective therapy for infections must be completed at least 2 weeks before the first dose. History of HIV infection or HIV antibody positive during screening; positive treponema pallidum antibody during screening; active pulmonary tuberculosis (evidenced by chest imaging or other relevant examinations within 3 months prior to first administration or during screening indicating active TB infection); active hepatitis during screening (positive hepatitis B surface antigen [HBsAg], or positive hepatitis B core antibody [HBcAb] with HBV DNA ≥30 IU/mL, or positive hepatitis C antibody [HCV Ab] with positive HCV RNA)
  • Use of B-cell or plasma-cell targeting agents within 3 months prior to the first administration of the investigational drug or expected use during the study period
  • Receipt of antithymocyte globulin or antilymphocyte globulin within 6 months prior to the first administration of the investigational drug
  • Treatment with tacrolimus, sirolimus, cyclophosphamide, anti-CD52 monoclonal antibodies, or similar agents within 4 weeks or 5 half-lives (whichever is shorter) prior to the first administration of the investigational drug
  • Planned participation in another clinical trial or prior exposure to another investigational product within less than 4 weeks or 5 half-lives (whichever is shorter) before the first dose
  • Vaccination with live attenuated vaccines within 4 weeks prior to the first administration of the investigational drug or planned during the study period, or COVID-19 vaccination within 7 days prior to first administration
  • Prior exposure to CD38-targeted therapy
  • Pregnant or breastfeeding women, or women planning to become pregnant or breastfeed during the study; female subjects of childbearing potential and male subjects with partners of childbearing potential who are unwilling to use highly effective contraception (see Appendix 3 for specific methods) throughout the study (from signing the ICF to 6 months after the last dose of study drug), or who plan to donate eggs or sperm during the study
  • Patients with congenital bone marrow failure syndromes
  • Patients with clonal chromosomal abnormalities characteristic of myelodysplastic syndrome (MDS) (except +8, 20q-, and -Y)
  • Presence of active bleeding in the gastrointestinal tract, respiratory tract, central nervous system, or other sites
  • History of significant clinical diseases that, in the investigator's judgment, would pose a safety risk for the subject's participation or affect the evaluation of efficacy or safety if the disease/condition worsens during the study. Examples include:; 7.1 Cardiovascular disease: acute myocardial infarction or unstable angina within the past year, severe arrhythmias (such as frequent multifocal PVCs, ventricular tachycardia, ventricular fibrillation, etc.), congestive heart failure, arterial or venous thrombosis, NYHA Class III-IV cardiac function; 7.2 History of psychiatric disorders or severe cerebrovascular disease or cognitive sequelae
  • Any other conditions deemed unsuitable for participation in this study by the investigator
  • Patients with bone marrow reticulin staining ≥ Grade 2
  • Patients with paroxysmal nocturnal hemoglobinuria (PNH) clone ≥50% or with active hemolysis

Ennek a vizsgálatnak nincs helyszíne itt: Egyesült Államok.

Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.

A vizsgálatról

Mit akar kideríteni a vizsgálat

This study consists of two phases, phase Ib and phase II. The primary objective of phase Ib is to evaluate the safety and tolerability of multiple doses of daratumumab in patients with refractory aplastic anemia. The primary objective of phase II is to preliminarily assess the efficacy of multiple doses of daratumumab in patients with refractory aplastic anemia. Secondary objectives include evaluation of other efficacy endpoints, safety (phase II), and pharmacodynamic characteristics of multiple doses of daratumumab in these patients. The exploratory objective is to assess biological functional changes in peripheral blood and bone marrow before and after daratumumab treatment.

A vizsgálat csoportja

  • After enrollment, patients will receive daratumumab treatment.A vizsgált kezelés

    This study is designed as a seamless Phase Ib/II trial. The target population is adult patients with refractory aplastic anemia (AA), who must meet the criteria for refractory AA at enrollment. After enrollment, patients will receive daratumumab treatment.

    Kezelés: Daratumumab

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
An Ib/II Phase Clinical Study Evaluating the Safety and Preliminary Efficacy of Daratumumab in Patients With Refractory Aplastic Anemia
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
A regiszteradat frissítve
2026. november 6.